Quality e-Newsletter
Intelligence Unit Special Reports Special Events Subscribe Sponsored Departments Follow Us

Twitter Facebook LinkedIn RSS

FDA Adds Contrast Agent Label Warning

Cheryl Clark, for HealthLeaders Media, September 13, 2010

The FDA advised providers to record the specific GBCA and the dosage given to each patient.




  • Do not exceed recommended dose and prior to re-administration, allow sufficient time for elimination from body, respecting half life.
  • For patients who are receiving hemodialysis, consider promptly initiating hemodialysis following GBCA administration.
  • Present patients with a list of symptoms.
  • Report adverse events with GBCAs to Fed's MedWatch program.



    Cheryl Clark is senior quality editor and California correspondent for HealthLeaders Media. She is a member of the Association of Health Care Journalists.

    Comments are moderated. Please be patient.